Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
NCT00979212 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without panitumumab in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see how well they work when given with or without panitumumab in treating patients with stage IIIA non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG panitumumab
- DRUG paclitaxel
- PROCEDURE surgery
Study Locations (20)
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center — Baltimore
- St. Agnes Hospital Cancer Center — Baltimore
- Cancer Institute at St. Joseph Medical Center — Towson
Ohio
- Summa Center for Cancer Care at Akron City Hospital — Akron
- Charles M. Barrett Cancer Center at University Hospital — Cincinnati
- Cleveland Clinic Taussig Cancer Center — Cleveland
California
- Mercy Cancer Center at Mercy San Juan Medical Center — Carmichael
- Radiological Associates of Sacramento Medical Group, Incorporated — Sacramento
Minnesota
- Fairview Southdale Hospital — Edina
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital — Minneapolis
New York
- NYU Cancer Institute at New York University Medical Center — New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center — Rochester
Colorado
- Penrose Cancer Center at Penrose Hospital — Colorado Springs
Kentucky
- Lucille P. Markey Cancer Center at University of Kentucky — Lexington
Louisiana
- CCOP - Ochsner — New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2011-02 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979212
The ClinicalTrials.gov registry entry for NCT00979212 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions — of which carboplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00979212 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Maryland, Ohio, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00979212 about?
NCT00979212 is a clinical study titled "Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as ...
What is the current status of trial NCT00979212?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2011-02. Estimated completion is 2022-05-20.
What conditions does trial NCT00979212 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00979212?
The interventions under investigation include: carboplatin (DRUG), panitumumab (DRUG), paclitaxel (DRUG), surgery (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00979212?
This trial is sponsored by Radiation Therapy Oncology Group, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00979212 being conducted?
This trial has 20 study locations across California, Colorado, Kentucky, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.